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CObjectives: Use of angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers results in decreased morbidity among patients
with chronic heart failure (CHF). Undersupply of medication could re-
sult in inadequate control of CHF, whereas oversupply of medication
could increase health-care costs and risks of toxicities. This study
aimed to determine the effects of medication supplies on health-
care costs and hospitalizations in patients with CHF receiving ang-
iotensin-converting enzyme inhibitors or angiotensin receptor
blockers. Methods: We retrospectively examined the electronic da-
tabase in a hospital in Thailand. Patients who were diagnosed with
CHF and who received angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers in the year 2003 were included. Med-
ication supplies were assessed by using the medication possession
ratio (MPR). The Cox proportional hazard model was used to deter-
mine the association of medication supply (appropriate supply: MPR
0.8 –1.2, oversupply: MPR  1.2, undersupply: MPR  0.8) with CHF-
related and all-cause hospitalizations. Health-care costs were com-
pared by using multiple linear regressions. All analyses were ad- O
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doi:10.1016/j.jval.2011.11.019usted for propensity score and other variables. Results: A total of 393
atients were included. Their mean age was 66 years, with 56% being
emales. Fifty-seven percent of the patients received an inappropriate
supply of medication. Undersupply of medication likely increased the
isks of CHF-related hospitalization with an adjusted hazard ratio of
.66 (95% confidence interval [CI] 0.80–3.46). The adjusted hazard ratio
f undersupply and oversupply of medication for all-cause hospitaliza-
ion was 1.13 (95% CI 0.74–1.73) and 3.19 (95%CI 0.66–15.47), respec-
ively. The total health-care costs in the undersupply and oversupply
roups were significantly greater than that in the appropriate-supply
roup: $49 (95% CI 32–66) and $103 (95% CI 32–173), respectively. Con-
lusions: Inappropriate medication supplies could increase the risks of
HF-related and all-cause hospitalizations. Both undersupply and
versupply of medication had significantly higher health-care costs.
eywords: chronic heart failure, hospitalization and health-care costs,
edication supply.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic heart failure (CHF) is a cardiovascular disease that se-
verely affects patients’ quality of life and incurs a substantial eco-
nomic burden on the health-care system [1]. The incidence and
prevalence of CHF continue to increase. The prevalence of CHF in
the Western world has been estimated as 1% to 2% [2], while it is
0.4% in Thailand [3]. About 5 million people in the United States
have heart failure, and more than 550,000 new patients are diag-
nosed yearly [4], resulting in 15 million medical visits and 6.5 mil-
lion hospital-days each year [5]. The total cost associated with CHF
in the United States was estimated to be $39.2 billion in the year
2010 [6].
The American College of Cardiology (ACC)/American Heart As-
sociation (AHA) clinical practice guidelines of 2009 recommended
angiotensin-converting enzymes (ACEIs) and angiotensin receptor
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Published by Elsevier Inc.blockers (ARBs) as one of the first-line pharmacotherapy required
for all patients with CHF without contraindications [7]. To achieve
optimal therapeutic benefits from medications, the right drug
should be prescribed and the right quantity needs to be sup-
plied. Inappropriate medication supply could lead to inade-
quate control of CHF. A number of research studies have dem-
onstrated that both types of inappropriate medication supply
can result in an increased risk of hospitalization and death and
increased health-care cost [8,9]. Oversupply of medications may
have negative effects because it can lead to overuse of medica-
tions in both the recipients of the prescription and people sur-
rounding them [8]. Even if patients do not consume or share
excess medications, oversupply still causes inefficient use of
health-care resources. The problem caused by undersupply has
a different nature from that caused by oversupply. Insufficient
provision of medications causes a noncompliance problem,
possibly leading to inadequate control of CHF. In the United
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S10 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 9 – S 1 4States, the prevalence of undersupply and oversupply in pa-
tients with CHF was 8% and 37%, respectively. Overall drug costs
in the undersupply group were 25% higher, while these were
18% higher in the oversupply group, compared with those in the
appropriate-supply supply [9]. Because the health-care system
n the United States is very unique, the findings from these
tudies [8,9] may not be directly applicable to countries in the
sia-Pacific region. Therefore, this study aimed to examine the
ffects of medication supplies on health-care costs and hospi-
alizations in patients with CHF receiving ACEIs or ARBs in the
hai health-care system.
Methods
Sources of data
A retrospective cohort study was conducted at a university-
affiliated hospital in Thailand. The study protocol was approved
by the Ethics Committee of the hospital. Electronic hospital da-
tabases including inpatient and outpatient databases, phar-
macy databases, and charge databases were used in this study.
Inpatient and outpatient databases contained information on
age, sex, health insurance, date of birth, and diagnostic codes
(International Statistical Classification of Diseases, 10th Revision
[ICD-10]). Pharmacy databases contained drug name, regimen,
and amount of medication per prescription. In addition, charge
databases contained drug, laboratory, medical service, and
other service charges.
Patients and study period
By using the electronic hospital database, we retrospectively iden-
tified patients diagnosed with the ICD-10 code of I-50.0 who re-
ceived either ACEIs or ARBs from January to December 2003. Each
patient’s index date was determined by the first prescription date.
To ensure that patients had continuity of care at this hospital, only
those patients who received at least two prescriptions of ACEIs or
ARBs within the first 6 months were included. In addition, they
must have been at least 18 years old. All included patients were
tracked from the index date for 2 years or until December 31, 2005.
To ensure that the outcomes of this study came after the exposure
of interest, medication supplies were measured within a year after
the index date, while the outcomes were measured in the follow-
ing year (Fig. 1).
Assessment of medication supplies
Medication supplies were determined by using the pharmacy
database. The magnitude of medication supplies was measured
by using the medication possession ratio (MPR) [10,11]. This
method determines the extent of medication possession during
the period of 1 year following the index prescription date. It is
calculated by dividing the number of days supply for a patient
over total days in the medication supplies measures period. In
Fig. 1 – Index date, medication supplies measures period,
and outcomes measures period.our study, we used 365 days as the number of days of the med-ication supplies measures period. We modified the means to
calculate the MPR by incorporating the changes in treatment
regimen and addition to the lag time among the prescription.
Therefore, the modified method was likely to provide an esti-
mated MPR that reflected the actual supply better than the tra-
ditional MPR [12].
Patients were classified as having an appropriate-medica-
tion supply (MPR 0.8 –1.2), undersupply (MPR  0.8), or oversup-
ply (MPR  1.2). We chose 0.8 as the threshold of undersupply
because studies have suggested that the therapeutic responses
to chronic treatments were preserved when patients took at
least 80% of the prescribed medications [13,14]. We chose 1.2 as
the threshold for oversupply because a number of studies sup-
ported the 20% buffer of medication supplies as the acceptable
level [8,15].
Outcome measures
Outcomes of interest in this study were CHF-related hospitaliza-
tion, all-cause hospitalization, and health-care costs. CHF-related
hospitalization was defined as hospitalized patients coded in
ICD-10 as I-50.0, while all-cause hospitalization was defined as any
hospitalizations occurring during the outcome measuring period.
The annual health-care costs were calculated by using only direct
medical costs because this study was undertaken by using the
hospital perspective. The total costs in our study included drug,
laboratory, medical service, and other service costs. The health-
care costs were calculated on the basis of the conversion of charge
to cost by using the ratio of cost to charge (0.58 for 2003, 0.57 for
2004, and 0.72 for 2005) [16].
Statistical analyses
Descriptive statistics were used to describe baseline characteris-
tics of included patients. Moreover, baseline characteristics were
compared by using the chi-square test and the analysis of vari-
ance. Kaplan-Meier survival estimates and the Cox proportional
hazard model were undertaken to examine the association be-
tween medication supplies and time to CHF-related and all-cause
hospitalizations. To determine the association between medica-
tion supplies and health-care costs, a multivariate linear regres-
sion was used with log-link transformation adjusted with the
Duan smearing factor [17]. To minimize potential differences be-
tween the three groups of medication supplies (undersupply, ap-Fig. 2 – A flow of patient selection.
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to estimate the probability of being in each medication supply
group. In this study, propensity score being the conditional prob-
ability of supplies of medications, it was calculated on the basis of
a nonparsimonious multinomial logistic regression by using all
variables as covariates. STATA package version 11.0 (StataCorp,
College Station, TX) was used for analysis.
Table 1 – Baseline characteristics of included patients.
Total Under
(MPR
Total number of patients 393 (100) 219
Demographics
Age (y), (mean  SD) 66.1  12.7 66.07
Gender
Males 173 (44.0) 95
Females 220 (56.0) 124
Health insurance
Civil Servant Medical Benefit Scheme 177 (45.0) 93
Universal Coverage scheme 209 (53.2) 121
Others 7 (1.8) 5
Medications
Aspirin 260 (66.2) 143
Spironolactone 68 (17.3) 37
Beta-blockers‡ 146 (37.2) 76
Lipid-lowering drugs§ 168 (42.8) 86
Digoxin 124 (31.6) 68
Diuretics 342 (87.0) 194
Clopidogrel 41 (10.4) 24
Comorbidities
Diabetes mellitus 117 (29.8) 63
Atrial fibrillation 100 (25.4) 61
Hypertension 271 (68.9) 145
Myocardial infarction 60 (15.3) 33
Ischemic heart disease 203 (51.6) 108
Renal failure 80 (20.4) 53
MPR, medication possession ratio.
* Calculated by F-test.
† Calculated by chi-square test.
‡ Beta-blockers included atenolol, bisoprolol, carvedilol, metoprolol,
§ Lipid-lowering drugs included atorvastatin, pravastatin, simvastat
 Diuretics included thiazide diuretics and furosemide.
Table 2 – The annual hospitalization rate and total average a
Undersupply
(MPR  0.8)
(n  219)
Ever hospitalization, n (%)
CHF-related 24 (11.0)
All-cause 55 (25.1)
Total annual health-care costs, mean  SD
Outpatient costs† 138  47
Inpatient costs† 1019  7107
Total annual health-care costs† 1157  7104
CHF, chronic heart failure; MPR, medication possession ratio.
* Calculated by chi-square test.
† $1  31.87 bahts.
‡ Calculated by F-test.Results
A total of 1012 patients diagnosed with CHF were identified. Forty-
four and 575 patients were excluded because of their age and no
continuity of care, respectively. A total of 393 patients were included
in the final analysis (Fig. 2). Patients were on average 66.112.7 years
of age; most of them were females (56%) and under the Universal
n (%) P-value
ly
.8)
Appropriate supply
(MPR 0.8–1.2)
Oversupply
(MPR  1.2)
) 168 (42.7) 6 (1.6)
.27 66.53  12.19 64.40  7.83 0.894*
0.377†
) 77 (45.8) 1 (16.7)
) 91 (54.2) 5 (83.3)
0.320†
) 83 (49.4) 1 (16.7)
) 83 (49.4) 5 (83.3)
2 (1.2) 0 (0.0)
) 113 (67.3) 4 (66.7) 0.916†
) 31 (18.4) 0 (0.0) 0.666†
) 69 (41.1) 1 (16.7) 0.280†
) 79 (47.0) 2 (40.0) 0.263†
) 56 (33.3) 0 (0.0) 0.253†
) 143 (85.1) 5 (83.3) 0.442†
) 17 (10.1) 0 (0.0) 0.932†
) 51 (30.4) 3 (50.0) 0.487†
) 38 (22.6) 1 (16.7) 0.551†
) 122 (72.6) 4 (66.7) 0.371†
) 27 (16.1) 0 (0.0) 0.079†
) 92 (54.8) 3 (50.0) 0.569†
) 26 (15.5) 1 (16.7) 0.105†
ropranolol.
d gemfibrozil.
al health-care costs categorized by medication supplies.
Appropriate supply
(MPR 0.8–1.2)
(n  168)
Over supply
(MPR  1.2)
(n  6)
P-value
12 (7.1) 0 (0) 0.348*
41 (24.4) 2 (33.3) 0.812*
138  44 180  47 0.077‡
341  1032 44  77 0.957‡
480  1028 224  65 0.359‡supp
 0
(55.7
 13
(43.4
(56.7
(42.5
(55.2
(2.3)
(65.3
(16.9
(34.6
(39.3
(31.1
(88.6
(11.0
(28.8
(27.8
(66.2
(15.1
(49.3
(24.2
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S12 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 9 – S 1 4Coverage health insurance scheme (53%) (Table 1). During the 1-year
observation period, 219 patients (56%) were categorized into the un-
dersupply group while 168 patients (43%) and 6 patients (2%) were
categorized in the appropriate-supply and oversupply groups, re-
spectively.
Medication supplies and hospitalizations
CHF-related and all-cause hospitalizations in patients with un-
dersupply of medication were 11% and 25%, respectively. In the
oversupply group, no CHF-related hospitalization was reported
while the percentage of all-cause hospitalization was 33
(Table 2).
Undersupply of medication was associated with an in-
creased risk of CHF-related hospitalization. Both oversupply
and undersupply of medication tended to have a higher risk of
all-cause hospitalization but without statistical significance.
Based on the propensity-adjusted Cox proportional hazard
model, undersupply of medication could increase the risk of
CHF-related and all-cause hospitalization, with an adjusted
hazard ratio of 1.66 (95% confidence interval [CI] 0.80 –3.46) for
CHF-related hospitalization and 1.13 (95% CI 0.74 –1.73) for all-
cause hospitalization. Patients with oversupply of medication
had an increased risk of all-cause hospitalization, with an ad-
justed hazard ratio of 3.19 (95% CI 0.66 –15.47). None of these
associations was statistically significant.
Medication supplies and total annual health-care cost
During the 1-year period of the study, total annual health-care cost
of patients with undersupply of medication was $253,328 ($1157
per person). Total cost incurred in the oversupply group was $1344
($224 per person), whereas it was $80,654 ($480 per person) in the
appropriate-supply group.
On average, patients who had oversupply of medication had
outpatient costs higher than those of the appropriate-supply
and undersupply groups, whereas patients with undersupply of
medication had inpatient costs higher than those of the appro-
priate-supply and over-supply patients (Table 2). The mean an-
nual health-care cost per patient among patients with under-
supply, appropriate supply, and oversupply of medication was
$1157  7104, $480 1028, and $224  65, respectively.
Compared with the appropriate-supply group, undersupply
and oversupply groups tended to have significantly higher costs
after controlling for covariates. On average, patients under the
oversupply group incurred an additional cost of $103 (95% CI 32.0–
173.4) while the undersupply group incurred an additional cost of
$49 (95% CI 31.8–66.0) when compared with patients in the appro-
Table 3 – The effects of medication supplies on CHF-related
supply.
Outcomes Unadjusted hazar
CHF-related hospitalization
Undersupply (MPR  0.8) 1.51 (0.75
Oversupply (MPR  1.2)† –
All-cause hospitalization
Undersupply (MPR  0.8) 1.26 (0.71
Oversupply (MPR  1.2) 1.68 (0.41
CHF, chronic heart failure; CI, confidence interval; MPR, medication p
* Covariates in this model include propensity score, age, sex, atrial fi
† The association of oversupply and CHF-related hospitalization
reason.
‡ Covariates in this model include propensity score, age, sex, atrial fipriate-supply group.Discussion
Our study revealed that more than half of the patients with CHF
had received an inappropriate –supply of medication, which
was associated with an increased risk of hospitalization and a
significant rise in total health-care costs. These results are con-
sistent with a number of studies previously published, which
found that about two-third of patients with CHF received an
inappropriate supply of medication [9,18]. Our study, therefore,
highlights the importance of such inappropriate supply of med-
ication and calls for strategies and interventions to minimize
such problems, which could result in less hospitalization and
costs.
Only 43% of all patients in this study received an appropriate
supply of medication. Several reasons may explain this large prev-
alence of inappropriate supply of medication. First, nonadherence
to medication is a possible blamer for the undersupply of medica-
tion. Nonadherence to medication might be caused by patient’s
perception of medical care, disease severity, unexpected adverse
events due to medications, health-care system, and others [19].
Regarding oversupply, it was postulated that prescribing practices
and patients’ behaviors might be one of the key contributors.
Sicker patients may seek more health-care services, visit more
physicians, and receive overlapping prescription. We believe that
inappropriate supplies of medication are caused not only by be-
havior of patients or physicians but also by the prescription-dis-
pensing system.
Similar to results of the Stroup et al. study [9], our results
showed that undersupply and oversupply of medications could
increase the risks of CHF-related and all-cause hospitalization.
Even though we focused on medication supplies, not particularly
all-cause hospitalizations compared with appropriate
io (95% CI) Adjusted hazard ratio (95% CI)
) 1.66 (0.80 – 3.46)*
–
) 1.13 (0.74 – 1.73)‡
) 3.19 (0.66 – 15.47)‡
ssion ratio.
tion, and use of spironolactone.
ot estimated because no patient was admitted with CHF-related
tion, renal failure, use of aspirin, and use of spironolactone.
Table 4 – The effects of medication supplies on total
annual health-care costs compared with appropriate
supply (US dollar).
Medication supplies Additional cost ($) (95% CI)
Undersupply (MPR  0.8) 48.9 (31.8 – 66.0)*
Oversupply (MPR  1.2) 102.7 (32.0 – 173.4)#
CI, confidence interval; MPR, medication possession ratio.
* Covariates in this model include propensity score, age, sex, health
insurance, diabetes mellitus, hypertension, myocardial infarc-
tion, renal failure, use of beta-blocker, and use of spironolactone.and
d rat
– 3.05
– 1.60
– 6.94
osse
brilla
was n# P  0.05.
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to medication showed that it could worsen CHF symptoms. Previ-
ous studies [20,21] found that the most commonly identified cause
of CHF worsening was drug nonadherence (21%–64%); moreover,
nonadherence was the precipitating factor of CHF exacerbation,
leading to hospitalization [22]. A previous study reported that pa-
tients with CHF with good adherence had less hospitalization
(13%) compared with nonadherers [23]. An excessive amount of
medication could cause to toxicities due to drug interaction and
side effects [24].
The significant rise in total annual health-care cost in the
inappropriate-supply group was reported in our study. This is
consistent with what has been found in the current literature
[9,23]. A number of studies have suggested that the cost of hos-
pitalization accounted for most of the total health-care cost in
patients with CHF [25,26]. Given the increased trend of more
hospitalization in the inappropriate group, this could partly ex-
plain the high cost found in this group. Efforts to reduce the
economic burden should be focused on hospitalization [25]. A
previous study reported that the total health-care cost in the
appropriate-supply group is 23% less than that in the inappro-
priate-supply group [23].
Our research work is one of a few studies evaluating the
clinical and economic impact of oversupply of medication in the
world. To our knowledge, this is the first one investigating this
issue in Asian countries. Oversupply of medication has been
recognized as one of the major factors driving total health-care
costs [27]. The overall economic burden associated with over-
supply of medication was estimated to be $32,000 per year. The
total financial loss nationwide can be estimated to be $5,000,000
per year, which was about 34% of the health-care expenditure
in the year 2005 [28]. Even though there are only a few patients
in the oversupply group, this study pointed out the importance
of the issue and called for more attention from practitioners and
policymakers to further explore this issue.
Some limitations existed in this study. First, these findings
rely on computerized hospital database. Any miscoding might
occur and result in inaccurate estimates. The hospital, however,
has reasons to use all measures to ensure high accuracy of da-
tabase as the data are used for claiming purposes. Therefore, we
still believe that the inaccuracy of estimates should be negligi-
ble. Second, some patients might seek medical care in other
hospitals. This might affect the estimates of MPR, hospitaliza-
tion, and costs. We attempted to minimize this issue by includ-
ing patients coming to seek medical care at this hospital and
who continually received the same medications. Third, the
findings from our study have limited generalizability. Our study
was conducted in a university-affiliated hospital, where clinical
practice might be different from that in other settings. Last,
because of the small number of patients in the oversupply
group, this study is underpowered to deliver a statistically
meaningful message about this patient group. According to our
findings, hospital policy should be implemented to make sure
that patients receive an appropriate supply of medication. Sev-
eral simple policies and interventions could be considered such
as constantly monitoring the pharmacy database and installing
system alerts when problems are found. These simple policies
could reduce the number of hospitalizations and ultimately
save health-care cost in the long run.
In conclusion, inappropriate medication supplies could in-
crease the risks of CHF-related and all-cause hospitalizations.
Both undersupply and oversupply of medication had significantly
higher health-care costs. The study highlighted the importance of
this issue to practitioners and policymakers, leading to prevent
the inappropriate supply. Table 3 and Table 4.Acknowledgments
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